Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 7, showing 10 Applications out of 66 total, starting on record 51, ending on 60

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

51.

ECCT/24/06/04   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
 
23-10-2024 View

52.

ECCT/16/08/03   IMPAACT 2001
    A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed project
 
27-10-2016 View

53.

ECCT/22/08/04   Protocol H06_01TP
    A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S. flexneri, serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2)           
Principal Investigator(s)
1. Deborah Chepngeno Langat Langat
Site(s) in Kenya
KEMRI WRP CRC KERICHO
 
23-11-2022 View

54.

ECCT/26/02/07   IMPAACT 2024
    Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV   
Principal Investigator(s)
1. LUCY Chepkurui Koech
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project(KEMRI/WRP)
 
27-08-2026 View

55.

ECCT/17/05/03   TDF IVR-002 Study
    Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Health Research & Development (Thika Partners Clinical Trial Site)
 
18-07-2017 View

56.

ECCT/10/09/05   A5225/ HiFLAC
    A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis       A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)   
Principal Investigator(s)
1. Deborah Chepngeno langat
Site(s) in Kenya
1.
 
08-02-2013 View

57.

ECCT/13/04/03   HIV-Malaria Study_A5297
        An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of    Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 .   
Principal Investigator(s)
1. Josphat K. Kosgei
Site(s) in Kenya
1. Kemri Walter Reed Project-Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
26-03-2013 View

58.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
28-03-2017 View

59.

ECCT/22/03/01   The \"NOVATION-1\" Trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19   
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. KEMRI Kericho (Kericho county)
4. KEMRI Siaya (Kisumu county)
5. Kenyatta National Hospital (Nairobi City county)
 
27-05-2022 View

60.

ECCT/18/06/01   Safety, Acceptability, and Feasibility of enterade® (SAFE)
    Safety, Acceptability, and Feasibility of enterade® in children at risk for environmental enteric dysfunction in Kakamega County, Kenya   
Principal Investigator(s)
1. Michael Benjamin Arndt
2. James Mukabi
Site(s) in Kenya
Kakamega County General Hospital (CGH)
 
02-10-2018 View